Regeneron Pharmaceuticals ((REGN)), Sanofi SA ((SNY)), Sanofi ((SNYNF)), Sanofi ((DE:SNW)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Regeneron Pharmaceuticals and Sanofi have announced a new clinical study, officially titled ‘A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Phase 3 Trial to Investigate the Efficacy, Safety, and Tolerability of Itepekimab in Adult Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps.’ The study aims to evaluate the effectiveness, safety, and tolerability of Itepekimab, an anti-IL-33 monoclonal antibody, in treating chronic rhinosinusitis with nasal polyps in adults.
The intervention being tested is Itepekimab, administered subcutaneously, with the purpose of reducing symptoms in patients with chronic rhinosinusitis with nasal polyps. The study also involves the use of mometasone furoate nasal spray as an add-on therapy.
The study design is interventional with a randomized, parallel-group model. It employs quadruple masking, meaning the participant, care provider, investigator, and outcomes assessor are all blinded to the treatment allocation. The primary purpose of the study is treatment-focused.
The study began on February 6, 2025, with primary completion estimated within 52 weeks. The last update was submitted on July 14, 2025. These dates are crucial for tracking the study’s progress and anticipating results.
This update could positively impact Regeneron and Sanofi’s stock performance, as successful results may enhance their market position in treating chronic rhinosinusitis. Investors should watch for developments, as competitors in the pharmaceutical industry are also advancing similar treatments.
The study is currently recruiting, and further details are available on the ClinicalTrials portal.